- Home
- SNAL vs IMRX Comparison
SNAL vs IMRX Comparison
Compare SNAL & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNAL
- IMRX
- Stock Information
- Founded
- SNAL 2000
- IMRX 2008
- Country
- SNAL United States
- IMRX United States
- Employees
- SNAL N/A
- IMRX N/A
- Industry
- SNAL Computer Software: Prepackaged Software
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- SNAL Technology
- IMRX Health Care
- Exchange
- SNAL Nasdaq
- IMRX Nasdaq
- Market Cap
- SNAL 59.1M
- IMRX 62.7M
- IPO Year
- SNAL 2022
- IMRX 2021
- Fundamental
- Price
- SNAL $0.88
- IMRX $1.52
- Analyst Decision
- SNAL
- IMRX Strong Buy
- Analyst Count
- SNAL 0
- IMRX 3
- Target Price
- SNAL N/A
- IMRX $11.00
- AVG Volume (30 Days)
- SNAL 58.7K
- IMRX 165.5K
- Earning Date
- SNAL 03-26-2025
- IMRX 03-20-2025
- Dividend Yield
- SNAL N/A
- IMRX N/A
- EPS Growth
- SNAL N/A
- IMRX N/A
- EPS
- SNAL 0.05
- IMRX N/A
- Revenue
- SNAL $84,467,047.00
- IMRX N/A
- Revenue This Year
- SNAL $26.80
- IMRX N/A
- Revenue Next Year
- SNAL N/A
- IMRX N/A
- P/E Ratio
- SNAL $17.65
- IMRX N/A
- Revenue Growth
- SNAL 38.69
- IMRX N/A
- 52 Week Low
- SNAL $0.52
- IMRX $1.00
- 52 Week High
- SNAL $3.42
- IMRX $3.83
- Technical
- Relative Strength Index (RSI)
- SNAL 28.19
- IMRX 38.83
- Support Level
- SNAL $1.57
- IMRX $1.60
- Resistance Level
- SNAL $1.70
- IMRX $1.91
- Average True Range (ATR)
- SNAL 0.17
- IMRX 0.11
- MACD
- SNAL -0.04
- IMRX 0.01
- Stochastic Oscillator
- SNAL 4.10
- IMRX 9.30
About SNAL Snail Inc.
Snail Inc is a global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.